Davion Healthcare (NASDAQ:DAVI – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Davion Healthcare Stock Performance
Davion Healthcare stock opened at $1.68 on Friday. Davion Healthcare has a 12-month low of $1.65 and a 12-month high of $12.30.
About Davion Healthcare
Davion Healthcare Plc is a digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments. The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion Healthcare Plc is based in DUBLIN.
Further Reading
- Five stocks we like better than Davion Healthcare
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Davion Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davion Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
